Consistent with the aforementioned literature, our study determined that the overexpression of CDKN2B-AS1 can decrease the expression of ADAM10, inhibit the progression of atherosclerosis and promote cholesterol efflux via binding to DNMT1. Here, CDKN2B is linked to atherosclerosis.